Du 26 au 28 mai 2025, le consortium ODIN a tenu sa troisième assemblée générale annuelle (AGA) à l'université de Lund, en Suède. Cet événement a réuni des chercheurs de ...
From 26 to 28 May 2025, the ODIN Consortium held its third Annual General Meeting (AGM) at Lund University, Sweden. The event brought together leading researchers, public health experts, and ...
Antimicrobial resistance (AMR) poses a significant threat to global health and economic stability. This report integrates human health burden projections with economic models to provide a comprehensive analysis of the ...
This rapid review, published by UKHSA, aims to identify and summarise evidence for the effectiveness of interventions to reduce infection-related harms for people who inject drugs in prisons and places ...
This rapid systematic review, published by the UKHSA’s All Hazards Public Health Response evidence review team, identified and summarised evidence of the effectiveness active case finding for tuberculosis in prisons ...
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
SPEAC announces the release of a comprehensive Companion Guide for the Brighton Collaboration Case Definition of Single Organ Cutaneous Vasculitis (SOCV). This new resource combines a wealth of tools and guidance to standardize vaccine safety assessments and pharmacovigilance efforts worldwide. Read more
CEPI and ANVISA hosted this workshop to update global regulators on the marketing authorisation and clinical development plans in preparation for phase IV studies and future global approvals. There was robust dialogue and participation from 18 countries representing 14 NRAs. Read more
In June 2024, CEPI convened a workshop in Nairobi, Kenya, to discuss epidemiology and modeling for human RVF vaccine development, bringing together representatives from RVF-endemic countries, global collaborators, and international health organizations. This paper summarizes the workshop discussions and priorities. Read more
The African Union has set an ambitious goal: by 2040 over 60% of the vaccines needed for Africa’s population should be produced locally. A sustainable supply chain for the specialized input materials that go into making vaccines will be required Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
